RGC Regencell Bioscience Holdings Limited
Financings ·
Regencell Bioscience agreed on May 19, 2026 to sell 985,222 ordinary shares at $20.30 each in a registered direct offering, about $20.0 million gross. Univest Securities, LLC is the sole placement agent and is also buying shares for its own account.
We have not published a story on Regencell Bioscience Holdings yet. When there is news, it will appear here.
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on research, development and commercialization of traditional Chinese medicine (TCM) for neurocognitive disorders and degeneration, specifically ADHD and ASD. It conducts its TCM research and development through Regencell Bioscience Limited, a Hong Kong subsidiary, which has entered into Strategic Partnership Agreements and a Supplemental Agreement with a TCM practitioner. Regencell Bioscience Holdings is a Cayman Islands holding company with no substantive operations other than holding the shares of its subsidiaries. Its stated goal is to save and improve the lives of patients, their families and caregivers, and to become a market leader for the best natural and holistic treatment globally. The company held a 60% equity interest in a joint venture, Regencell Bioscience Asia Limited, which ceased business on December 31, 2023. The text says that disposition did not have a material impact on its results of operations.
| Product or program | What it is | Stage |
|---|---|---|
| TCM programs for ADHD and ASD | Traditional Chinese medicine for neurocognitive disorders, specifically ADHD and ASD |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $1.3 million | $948,289 |
| Net income (loss) | -$11.7 million | -$3.6 million |
| Cash from operations | -$7.7 million | -$3.1 million |
| Cash and equivalents | $14.2 million | $2.4 million |
| Short-term investments | $2.5 million |
Our latest story on this, dated May 19, 2026: "Regencell Bioscience agrees to $20.0 million registered direct offering at $20.30 a share". The story links the filing or release it is based on. Read the story.
Regencell Bioscience Holdings Limited trades under the ticker RGC on NASDAQ.
Regencell Bioscience Holdings Limited is listed on NASDAQ.
The SEC Central Index Key (CIK) for Regencell Bioscience Holdings Limited is 1829667. Its filings are on SEC EDGAR.
495,884,376 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-10-07.
Our directory records Regencell Bioscience Holdings Limited under Hong Kong.
Our directory classifies Regencell Bioscience Holdings Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Regencell Bioscience Holdings Limited is KYG7487R1002.
aibio.space lists Regencell Bioscience Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on research, development and commercialization of traditional Chinese medicine (TCM) for neurocognitive disorders and degeneration, specifically ADHD and ASD. It conducts its TCM research and development through Regencell Bioscience Limited, a Hong Kong subsidiary, which has entered into Strategic Partnership Agreements and a Supplemental Agreement with a TCM practitioner.
TCM programs for ADHD and ASD: Traditional Chinese medicine for neurocognitive disorders, specifically ADHD and ASD
Regencell Bioscience Holdings Limited reported a net loss of $11.7 million for the fiscal year ended Jun 30, 2026, and used $7.7 million of cash in operations, per its annual report to the SEC.
$1.3 million in the fiscal year ended Jun 30, 2026, per its annual report.
$14.2 million in cash at Jun 30, 2026, per its 20-F.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio